Evidence map›Paper›PMID 26431226›Full record

ArticleEndocrinology2015

Development of an Enhanced Sensitivity Bead-Based Immunoassay for Real-Time In Vivo Detection of Pancreatic β-Cell Death.

Olivier R Costa, Geert Stangé, Katrijn Verhaeghen, Benedicte Brackeva, Ellen Nonneman, Christiane S Hampe, Zhidong Ling, Daniel Pipeleers, Frans K Gorus, Geert A Martens

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. The role of beta-cell dysfunction in early type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2020
    Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olivier R CostaDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Geert StangéDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Katrijn VerhaeghenDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Benedicte BrackevaDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Ellen NonnemanDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Christiane S HampeDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Zhidong LingDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Daniel PipeleersDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Frans K GorusDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.
Geert A MartensDiabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725.

Funding

ISLET CELL MEMBRANE ANTIBODIES IN DIABTESR01DK026190 · NIDDK · UNIVERSITY OF WASHINGTON · PI HAMPE, CHRISTIANE S · 1986 to 2016
$4.9M
NIDDK NIH HHS R01 DK026190
6 · The paper itself

Abstract

There is a clinical need for plasma tests to detect and quantify the in vivo destruction of pancreatic β-cells in type 1 diabetes. We previously developed a time-resolved fluorescence immunoassay (TRFIA) to glutamate decarboxylase 65 kDa (GAD65) (GAD65-TRFIA) that was able to detect the synchronous necrotic destruction of transplanted β-cells in the hours after their infusion in the liver. This GAD65-TRFIA, however, lacked sensitivity to detect continued β-cell rejection beyond this acute phase. The aim of present study was to gain at least an order of magnitude in analytical sensitivity by switching to Becton Dickinson cytometric bead array (CBA) (GAD65-CBA) enhanced sensitivity format, using the same couple of monoclonal antibodies. We compared the performances of GAD65-CBA and GAD65-TRFIA using Clinical and Laboratory Standards Institute protocols for linearity, imprecision, specificity, limit of detection, and functional sensitivity. We conducted a method comparison and assessed the biologic potential on samples from human recipients of islet grafts. The GAD65-CBA showed acceptable linearity and imprecision. Switching from TRFIA to CBA lowered functional sensitivity by a factor 35 and lowered limit of detection by a factor 11 with minimal need for method optimization. The enhanced sensitivity greatly expands the application domain of our biomarker and allowed for the first time to detect ongoing β-cell destruction up to at least 1 day after islet transplantation. We conclude that the GAD65-CBA is suitable for biological and clinical assessment of the real-time destruction of β-cells in intraportal transplantation.

Indexed as

ApoptosisIslets of Langerhans TransplantationBiomarkersDiabetes Mellitus, Type 1FluoroimmunoassayGlutamate DecarboxylaseHumansImmunoassayInsulin-Secreting CellsMicrospheresBiomarkersGlutamate Decarboxylaseglutamate decarboxylase 2

Identifiers

PMID26431226
PMCPMC5393343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.